Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
9.95
-0.85 (-7.83%)
Mar 31, 2025, 1:19 PM EDT - Market open
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 30, with a low estimate of 15 and a high estimate of 43. The average target predicts an increase of 201.66% from the current stock price of 9.95.
Analyst Consensus: Buy
* Price targets were last updated on Feb 27, 2025.
Analyst Ratings
The average analyst rating for Keros Therapeutics stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 3 | 3 | 3 |
| Hold | 0 | 0 | 4 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $28 → $26 | Buy | Maintains | $28 → $26 | +161.44% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $40 | Strong Buy | Maintains | $47 → $40 | +302.21% | Feb 27, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $40 → $15 | Buy | Maintains | $40 → $15 | +50.83% | Jan 17, 2025 |
| Wedbush | Wedbush | Buy → Hold Downgrades $47 → $15 | Buy → Hold | Downgrades | $47 → $15 | +50.83% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
4.14M
from 3.55M
Increased by 16.65%
Revenue Next Year
8.59M
from 4.14M
Increased by 107.46%
EPS This Year
-3.52
from -5.00
EPS Next Year
-4.27
from -3.52
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.0M | 42.0M | 110.5M | ||
| Avg | 4.1M | 8.6M | 25.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,083.1% | 914.2% | 1,185.6% | ||
| Avg | 16.6% | 107.5% | 195.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.91 | -1.70 | -2.46 | ||
| Avg | -3.52 | -4.27 | -4.49 | ||
| Low | -5.59 | -5.90 | -6.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.